|drug76||80 ppm Nitric Oxide delivered through LungFit Delivery System Wiki||1.00|
|drug3321||Remdesivir placebo Wiki||0.71|
|D012120||Respiration Disorders NIH||0.23|
|D012140||Respiratory Tract Diseases NIH||0.19|
|D011024||Pneumonia, Viral NIH||0.11|
There is one clinical trial.
The purpose of this open label, 2-phase, study is to obtain information on the safety of 80 ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.
Description: Time to deterioration as measured by any one of the following: need for non-invasive ventilation need for high flow nasal cannula (HFNC) or need for intubation Death from any causeMeasure: Time to deterioration Time: up to 14 days
Description: Time to patient having stable oxygen saturation (SpO2) of greater than 92% for longer than 3 hr on room airMeasure: Time to stable oxygen saturation Time: up to 14 days
Description: Treatment Emergent Adverse Events and SAEs - safety evaluation for 30 days after last inhalation treatmentMeasure: Treatment Emergent Adverse Events and SAEs Time: 30 days after last inhalation treatment
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports